Eli Lilly And Company revenue by segment LLY

Annual Quarterly

Eli Lilly And Company splits its revenue into 9 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $61.0 billion, 94% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	86,462	65,179	45,043	34,124	28,541	28,318	24,540	22,320	21,493	19,974	21,222
Product	80,806 +47.8% share 93.5%	60,958 +49.6% share 93.5%	40,748 +41.4% share 90.5%	28,814 +13.2% share 84.4%	25,463 -1.9% share 89.2%	25,958 +14.4% share 91.7%	22,695 +11.4% share 92.5%	20,377 +2.6% share 91.3%	19,866 +5.8% share 92.4%	18,776 share 94.0%	—
Collaborationand Other Revenue	5,656 +19.4% share 6.5%	4,221 -1.7% share 6.5%	4,295 -19.1% share 9.5%	5,310 +72.5% share 15.6%	3,079 +30.4% share 10.8%	2,360 +27.9% share 8.3%	1,845 -5.0% share 7.5%	1,942 +19.4% share 8.7%	1,627 +35.9% share 7.6%	1,197 share 6.0%	—
Jardiance	4,693 +21.5% share 5.4%	3,432 +2.7% share 5.3%	3,341 +21.7% share 7.4%	2,745 +32.9% share 8.0%	2,066 +38.6% share 7.2%	1,491 +29.2% share 5.3%	1,154 +22.2% share 4.7%	944 +43.4% share 4.2%	658 +47.1% share 3.1%	448 share 2.2%	—
COVID19 Antibodies	—	—	—	—	2,020 -9.8% share 7.1%	2,240 +157.1% share 7.9%	871 share 3.6%	—	—	—	—
Olumiant	—	—	957 +3.8% share 2.1%	923 +11.1% share 2.7%	830 -25.5% share 2.9%	1,115 +74.5% share 3.9%	639 +49.7% share 2.6%	427 +110.8% share 1.9%	202 +342.1% share 0.9%	46 share 0.2%	—
Basaglar	—	—	677 -7.1% share 1.5%	728 -4.2% share 2.1%	760 -14.8% share 2.7%	892 -20.6% share 3.2%	1,124 +1.1% share 4.6%	1,113 +38.9% share 5.0%	801 +85.4% share 3.7%	432 share 2.2%	—
TYVYT	—	—	526 +33.7% share 1.2%	393 +34.1% share 1.2%	293 -29.8% share 1.0%	418 +35.4% share 1.5%	309 +130.4% share 1.3%	134 share 0.6%	—	—	—
Trajenta BI	—	—	—	387 +0.8% share 1.1%	384 +3.0% share 1.3%	372 +3.9% share 1.3%	358 -39.3% share 1.5%	591 +2.8% share 2.6%	575 +6.8% share 2.7%	538 share 2.7%	—
Royalty	—	—	—	192 +17.3% share 0.6%	163 -6.6% share 0.6%	175 +29.1% share 0.6%	136 -55.0% share 0.6%	302 -0.6% share 1.4%	303 +109.2% share 1.4%	145 share 0.7%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LLY (NYSE)
Fiscal year ends: December 31
Incorporated in: IN
Headquarters: Indianapolis, IN
SEC filer status: Large accelerated filer
SEC CIK: 59478
Former names: LILLY ELI & CO (until Oct 25, 2019); LILLY ELI & CO ET AL (until Oct 14, 1994)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.